Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

অনুরূপ উপাদানগুলি

• Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
  অনুযায়ী: Patel, Hitisha K., অন্যান্য
  প্রকাশিত: (2019)
• Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
  অনুযায়ী: Conlan, Maureen G., অন্যান্য
  প্রকাশিত: (2020)
• Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
  অনুযায়ী: Conlan, Maureen G., অন্যান্য
  প্রকাশিত: (2020)
• Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
  অনুযায়ী: Wardell, Suzanne E., অন্যান্য
  প্রকাশিত: (2015)
• A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
  অনুযায়ী: Jager, Agnes, অন্যান্য
  প্রকাশিত: (2020)